Topic summary
Dana–Farber Cancer Institute
Dana–Farber Cancer Institute (DFCI) is a comprehensive cancer treatment and research center in Boston, Massachusetts. Dana–Farber is the founding member of the Dana–Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and is a principal teaching affiliate and research institute of Harvard Medical School.
As of 2024, Dana–Farber is ranked as the sixth-best cancer hospital in the US. Two Nobel laureates in Physiology or Medicine are among its past and present faculty.
In 2024, an investigation revealed evidence of research misconduct in dozens of studies authored by Dana–Farber researchers, including then-president and chief executive officerLaurie Glimcher, the executive vice president and chief operating officer, and the research integrity officer. In response to these findings, Dana–Farber retracted seven papers and corrected 31 others. In October 2024, Laurie Glimcher stepped down as President and CEO. In December 2025, Dana Farber agreed to pay $15 million to settle the fraud allegations, including over $2.5 million to scientist Sholto David.